HIV-AIDS: Much Accomplished, Much to Do

Overview

Journal Nat Immunol

Date 2013 Oct 23

PMID 24145780

Citations 24

Authors

Anthony S Fauci

Gregory K Folkers

Carl W Dieffenbach

Affiliations

Soon will be listed here.

Abstract

As a result of decades of research-driven breakthroughs in basic and clinical science and recent advances in the broad-scale implementation of interventions for the prevention and treatment of infection with HIV, a turning point has been reached in the global HIV-AIDS pandemic. To end the pandemic and achieve the goal of an AIDS-free generation, researchers and clinicians must follow the dual pathway of optimizing the implementation of existing prevention and treatment interventions and discovering with basic and clinical research new and effective tools in both of these arenas.

Citing Articles

Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.

Diepstra K, Barr L, Palm D, Hogg E, Mollan K, Henley L AIDS Res Hum Retroviruses. 2021; 37(6):489-501.

PMID: 33472545 PMC: 8213012. DOI: 10.1089/AID.2020.0222.

Using discrete choice experiments to design interventions for heterogeneous preferences: protocol for a pragmatic randomised controlled trial of a preference-informed, heterogeneity-focused, HIV testing offer for high-risk populations.

Ostermann J, Njau B, Hobbie A, Mtuy T, Masaki M, Shayo A BMJ Open. 2020; 10(11):e039313.

PMID: 33158826 PMC: 7651730. DOI: 10.1136/bmjopen-2020-039313.

HIV Prevention in Adolescents and Young People in the Eastern and Southern African Region: A Review of Key Challenges Impeding Actions for an Effective Response.

Govender K, Masebo W, Nyamaruze P, Cowden R, Schunter B, Bains A Open AIDS J. 2018; 12:53-67.

PMID: 30123385 PMC: 6062910. DOI: 10.2174/1874613601812010053.

Reduced Chronic Lymphocyte Activation following Interferon Alpha Blockade during the Acute Phase of Simian Immunodeficiency Virus Infection in Rhesus Macaques.

Carnathan D, Lawson B, Yu J, Patel K, Billingsley J, Tharp G J Virol. 2018; 92(9).

PMID: 29467313 PMC: 5899190. DOI: 10.1128/JVI.01760-17.

If We Build It, Will They Come? Perceptions of HIV Cure-Related Research by People Living with HIV in Four U.S. Cities: A Qualitative Focus Group Study.

Sylla L, Evans D, Taylor J, Gilbertson A, Palm D, Auerbach J AIDS Res Hum Retroviruses. 2017; 34(1):56-66.

PMID: 29198134 PMC: 5771509. DOI: 10.1089/AID.2017.0178.

References

Kwong P, Mascola J . Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012; 37(3):412-25. PMC: 4706166. DOI: 10.1016/j.immuni.2012.08.012. View

Baeten J, Grant R . Use of antiretrovirals for HIV prevention: what do we know and what don't we know?. Curr HIV/AIDS Rep. 2013; 10(2):142-51. PMC: 3644362. DOI: 10.1007/s11904-013-0157-9. View

Moyer V . Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013; 159(1):51-60. DOI: 10.7326/0003-4819-159-1-201307020-00645. View

Paltiel A, Freedberg K, Scott C, Schackman B, Losina E, Wang B . HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009; 48(6):806-15. PMC: 2876329. DOI: 10.1086/597095. View

Johnston M, Fauci A . HIV vaccine development--improving on natural immunity. N Engl J Med. 2011; 365(10):873-5. DOI: 10.1056/NEJMp1107621. View

. Vital signs: HIV infection, testing, and risk behaviors among youths - United States. MMWR Morb Mortal Wkly Rep. 2012; 61(47):971-6. View

Davey Jr R, Bhat N, Yoder C, Chun T, Metcalf J, Dewar R . HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A. 1999; 96(26):15109-14. PMC: 24781. DOI: 10.1073/pnas.96.26.15109. View

Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C . Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013; 9(3):e1003211. PMC: 3597518. DOI: 10.1371/journal.ppat.1003211. View

Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell M . High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013; 339(6122):966-71. PMC: 4255272. DOI: 10.1126/science.1228160. View

10.

Chun T, Fauci A . Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A. 1999; 96(20):10958-61. PMC: 34225. DOI: 10.1073/pnas.96.20.10958. View

11.

Gray R, Kigozi G, Kong X, Ssempiija V, Makumbi F, Wattya S . The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS. 2012; 26(5):609-15. PMC: 4296667. DOI: 10.1097/QAD.0b013e3283504a3f. View

12.

Okwundu C, Uthman O, Okoromah C . Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev. 2012; (7):CD007189. PMC: 11324012. DOI: 10.1002/14651858.CD007189.pub3. View

13.

Gardner E, McLees M, Steiner J, Del Rio C, Burman W . The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011; 52(6):793-800. PMC: 3106261. DOI: 10.1093/cid/ciq243. View

14.

Deeks S, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N . Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012; 12(8):607-14. PMC: 3595991. DOI: 10.1038/nri3262. View

15.

Nakagawa F, May M, Phillips A . Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2012; 26(1):17-25. DOI: 10.1097/QCO.0b013e32835ba6b1. View

16.

Cohen J . HIV/AIDS. Early treatment may have cured infant of HIV infection. Science. 2013; 339(6124):1134. DOI: 10.1126/science.339.6124.1134. View

17.

Haynes B, B Gilbert P, McElrath M, Zolla-Pazner S, Tomaras G, Alam S . Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366(14):1275-86. PMC: 3371689. DOI: 10.1056/NEJMoa1113425. View

18.

Hall H, Holtgrave D, Maulsby C . HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS. 2012; 26(7):893-6. DOI: 10.1097/QAD.0b013e328351f73f. View

19.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R . Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209-20. DOI: 10.1056/NEJMoa0908492. View

20.

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. PMC: 3200068. DOI: 10.1056/NEJMoa1105243. View